Amgen Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Amgen Inc. (AMGN) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $5.34 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-04-25
- Amgen Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $5.34B, a 2.77% increase year-over-year.
- Amgen Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $5.57B, a 1.66% decline year-over-year.
- Amgen Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $5.45B, a 1.14% decline year-over-year.
- Amgen Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $5.57B, a 1.83% increase year-over-year.
- Amgen Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $21.80B, a 0.44% decline from fiscal 2016.
- Amgen Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $21.89B, a 4.53% increase from fiscal 2015.
- Amgen Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $20.94B, a 8.37% increase from fiscal 2014.
- Amgen Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $19.33B.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $5.34B 10-Q · filed 2018-04-25 | $10.91B derived: sum of 2 quarters · filed 2018-04-25 | $16.36B derived: sum of 3 quarters · filed 2018-04-25 | $21.94B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-12-31 | $5.57B 10-K · filed 2018-02-13 | $11.02B derived: sum of 2 quarters · filed 2018-02-13 | $16.60B derived: sum of 3 quarters · filed 2018-02-13 | $21.80B 10-K · filed 2018-02-13 |
| 2017-09-30 | $5.45B 10-K · filed 2018-02-13 | $11.03B derived: sum of 2 quarters · filed 2018-02-13 | $16.23B 10-Q · filed 2017-10-26 | $21.89B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-06-30 | $5.57B 10-K · filed 2018-02-13 | $10.77B 10-Q · filed 2017-07-26 | $16.44B derived: sum of 3 quarters · filed 2018-04-25 | $21.95B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-03-31 | $5.20B 10-Q · filed 2018-04-25 | $10.86B derived: sum of 2 quarters · filed 2018-04-25 | $16.38B derived: sum of 3 quarters · filed 2018-04-25 | $21.85B derived: sum of 4 quarters · filed 2018-04-25 |
| 2016-12-31 | $5.66B 10-K · filed 2018-02-13 | $11.18B derived: sum of 2 quarters · filed 2018-02-13 | $16.65B derived: sum of 3 quarters · filed 2018-02-13 | $21.89B 10-K · filed 2018-02-13 |
| 2016-09-30 | $5.52B 10-K · filed 2018-02-13 | $10.99B derived: sum of 2 quarters · filed 2018-02-13 | $16.23B 10-Q · filed 2017-10-26 | $21.56B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $5.47B 10-K · filed 2018-02-13 | $10.71B 10-Q · filed 2017-07-26 | $16.04B derived: sum of 3 quarters · filed 2018-02-13 | $21.56B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $5.24B 10-K · filed 2018-02-13 | $10.57B derived: sum of 2 quarters · filed 2018-02-13 | $16.08B derived: sum of 3 quarters · filed 2018-02-13 | $21.31B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $5.33B 10-K · filed 2017-02-14 | $10.85B derived: sum of 2 quarters · filed 2017-02-14 | $16.07B derived: sum of 3 quarters · filed 2017-02-14 | $20.94B 10-K · filed 2018-02-13 |
| 2015-09-30 | $5.52B 10-K · filed 2017-02-14 | $10.74B derived: sum of 2 quarters · filed 2017-02-14 | $15.62B 10-Q · filed 2016-10-28 | $20.79B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $5.22B 10-K · filed 2017-02-14 | $10.10B 10-Q · filed 2016-07-29 | $15.27B derived: sum of 3 quarters · filed 2017-02-14 | $20.12B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $4.87B 10-K · filed 2017-02-14 | $10.05B derived: sum of 2 quarters · filed 2017-02-14 | $14.90B derived: sum of 3 quarters · filed 2017-02-14 | $19.84B derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $5.17B 8-K · filed 2016-10-31 | $10.02B derived: sum of 2 quarters · filed 2016-10-31 | $14.97B derived: sum of 3 quarters · filed 2016-10-31 | $19.33B 10-K · filed 2017-02-14 |
| 2014-09-30 | $4.85B 8-K · filed 2016-10-31 | $9.80B derived: sum of 2 quarters · filed 2016-10-31 | $14.15B 10-Q · filed 2015-11-02 | $18.95B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $4.95B 8-K · filed 2016-10-31 | $9.30B 10-Q · filed 2015-08-05 | $14.10B derived: sum of 3 quarters · filed 2016-10-31 | $18.75B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $4.36B 8-K · filed 2016-10-31 | $9.15B derived: sum of 2 quarters · filed 2016-10-31 | $13.80B derived: sum of 3 quarters · filed 2016-10-31 | $18.40B derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | $4.80B 10-K · filed 2015-02-19 | $9.45B derived: sum of 2 quarters · filed 2015-02-19 | $14.04B derived: sum of 3 quarters · filed 2015-02-19 | $18.19B 8-K · filed 2016-10-31 |
| 2013-09-30 | $4.65B 10-K · filed 2015-02-19 | $9.24B derived: sum of 2 quarters · filed 2015-02-19 | $13.39B 10-Q · filed 2014-10-29 | $17.73B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $4.59B 10-K · filed 2015-02-19 | $8.75B 10-Q · filed 2014-08-05 | $13.08B derived: sum of 3 quarters · filed 2015-02-19 | $17.28B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $4.15B 10-K · filed 2015-02-19 | $8.49B derived: sum of 2 quarters · filed 2015-02-19 | $12.69B derived: sum of 3 quarters · filed 2015-02-19 | $16.89B derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $4.34B 10-K · filed 2014-02-24 | $8.54B derived: sum of 2 quarters · filed 2014-02-24 | $12.74B derived: sum of 3 quarters · filed 2014-02-24 | $16.64B 10-K · filed 2015-02-19 |
| 2012-09-30 | $4.20B 10-K · filed 2014-02-24 | $8.40B derived: sum of 2 quarters · filed 2014-02-24 | $12.30B 10-Q · filed 2013-10-29 | $16.21B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $4.20B 10-K · filed 2014-02-24 | $8.10B 10-Q · filed 2013-08-06 | $12.01B derived: sum of 3 quarters · filed 2014-02-24 | $15.88B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | $3.90B 10-K · filed 2014-02-24 | $7.81B derived: sum of 2 quarters · filed 2014-02-24 | $11.69B derived: sum of 3 quarters · filed 2014-02-24 | $15.58B derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $3.91B 10-K · filed 2013-02-27 | $7.78B derived: sum of 2 quarters · filed 2013-02-27 | $11.68B derived: sum of 3 quarters · filed 2013-02-27 | $15.29B 10-K · filed 2014-02-24 |
| 2011-09-30 | $3.88B 10-K · filed 2013-02-27 | $7.77B derived: sum of 2 quarters · filed 2013-02-27 | $11.39B 10-Q · filed 2012-11-06 | $15.15B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $3.89B 10-K · filed 2013-02-27 | $7.51B 10-Q · filed 2012-08-08 | $11.27B derived: sum of 3 quarters · filed 2013-02-27 | $15.03B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $3.62B 10-K · filed 2013-02-27 | $7.38B derived: sum of 2 quarters · filed 2013-02-27 | $11.14B derived: sum of 3 quarters · filed 2013-02-27 | $14.75B derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $3.76B 10-K · filed 2012-02-29 | $7.52B derived: sum of 2 quarters · filed 2012-02-29 | $11.13B derived: sum of 3 quarters · filed 2012-02-29 | $14.66B 10-K · filed 2013-02-27 |
| 2010-09-30 | $3.76B 10-K · filed 2012-02-29 | $7.37B derived: sum of 2 quarters · filed 2012-02-29 | $10.90B 10-Q · filed 2011-11-04 | $14.64B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $3.61B 10-K · filed 2012-02-29 | $7.14B 10-Q · filed 2011-08-08 | $10.88B derived: sum of 3 quarters · filed 2012-02-29 | $14.62B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $3.53B 10-K · filed 2012-02-29 | $7.27B derived: sum of 2 quarters · filed 2012-02-29 | $11.01B derived: sum of 3 quarters · filed 2012-02-29 | $14.64B derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $3.74B 10-K · filed 2011-02-25 | $7.48B derived: sum of 2 quarters · filed 2011-02-25 | $11.11B derived: sum of 3 quarters · filed 2011-02-25 | $14.35B 10-K · filed 2012-02-29 |
| 2009-09-30 | $3.74B 10-K · filed 2011-02-25 | $7.37B derived: sum of 2 quarters · filed 2011-02-25 | $10.61B 10-Q · filed 2010-11-08 | $14.28B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-06-30 | $3.63B 10-K · filed 2011-02-25 | $6.87B 10-Q · filed 2010-08-09 | $10.55B derived: sum of 3 quarters · filed 2011-02-25 | $14.33B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-03-31 | $3.24B 10-K · filed 2011-02-25 | $6.91B derived: sum of 2 quarters · filed 2011-02-25 | $10.70B derived: sum of 3 quarters · filed 2011-02-25 | $14.39B derived: sum of 4 quarters · filed 2011-02-25 |
| 2008-12-31 | $3.67B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $7.46B derived: sum of 2 quarters · filed 2011-02-25 | $11.15B derived: sum of 3 quarters · filed 2011-02-25 | $14.69B 10-K · filed 2011-02-25 |
| 2008-09-30 | $3.78B 10-Q · filed 2009-11-06 | $7.48B derived: sum of 2 quarters · filed 2009-11-06 | $11.01B 10-Q · filed 2009-11-06 | |
| 2008-06-30 | $3.69B 10-Q · filed 2009-08-10 | $7.23B 10-Q · filed 2009-08-10 | ||
| 2007-12-31 | $14.31B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |